Winter Scientific welcomes inquiries from investors, industry partners, researchers, clinicians, patient organisations, and members of the media. Advancing meaningful therapies for idiopathic pulmonary fibrosis depends on close engagement with the broader scientific and patient community, and we value every conversation that helps move that mission forward.

If you are exploring investment or collaboration opportunities, please include a brief introduction to your organisation and your area of interest, and a member of the team will respond directly. For scientific, academic, or media enquiries, we are equally pleased to hear from you.